Company To Webcast Annual Meeting on October 25
WINNIPEG, Manitoba -(October 25, 2004) Medicure
Inc. (TSX:MPH/Amex:MCU), a cardiovascular drug discovery and development
company is pleased to announce that it will be presenting at the
Rodman & Renshaw Techvest Global Healthcare Conference at the
Waldorf=Astoria Hotel in New York City on Thursday, October 28.
The Conference is the second of two Rodman & Renshaw Techvest
Global Healthcare Conferences that Medicure will have participated
in this year - the first was in London, England in May. The Rodman
& Renshaw conferences bring together medical and scientific
experts, executives from European and North American biotechnology
and pharmaceutical companies, and institutional investors, analysts
and venture capitalists who follow the life sciences sector, to
hear corporate presentations from leading biotech companies from
around the world. Albert D. Friesen, Ph.D., Medicure's President
and CEO will deliver the Company's presentation at 10:05 a.m., New
York time.
LIVE WEBCAST OF ANNUAL MEETING
Medicure is also announcing today that it will conduct a live audio
webcast of its Annual General and Special Meeting of Shareholders
being held in conjunction with the Canadian Cardiovascular Congress
in Calgary, Alberta on Monday, October 25, 2004. Interested parties
may listen to the webcast beginning at 4:30 pm Eastern Time by visiting
the following web site: http://www.ccnmatthews.com/Medicure/AGM
or by following the links on Medicure's corporate web site at www.medicureinc.com.
About Medicure Inc.
Medicure Inc. is a cardiovascular drug discovery and development
Company focused on developing effective therapeutics for unmet needs
in the field of cardiovascular medicine. In its successful Phase
II clinical trial, MEND-1, the Company's lead drug, MC-1, demonstrated
cardioprotective effects and safety in high-risk patients undergoing
angioplasty. The results from this clinical trial showed that MC-1
significantly reduces ischemic heart damage associated with the
angioplasty procedure. Proceeding from this positive outcome, Medicure's
ongoing Phase II/III MEND-CABG clinical trial is evaluating the
cardioprotective and neuroprotective effects of MC-1 in patients
undergoing high-risk Coronary Artery Bypass Graft (CABG) surgery.
The cardiovascular market is the largest pharmaceutical sector with
annual global sales of over US $70 billion.
The Company's second product candidate, MC-4232, is a unique combination
drug for the treatment of diabetic patients with hypertension. The
co-existing conditions of diabetes and hypertension present a major
increase in risk of cardiovascular complications, including coronary
artery disease, peripheral artery disease, retinopathy, nephropathy
and stroke. MC-4232 is a novel combination product that combines
MC-1's cardioprotective properties with an ACE Inhibitor, the most
common form of hypertensive therapy. In addition to cardioprotection,
this product has also demonstrated potential to provide further
blood pressure lowering effects and reduction in glycated hemoglobin
(HbA1c), the primary measure of blood glucose control. The Company
is currently enrolling patients in the Phase II MATCHED study (MC-1
and ACE Therapeutic Combination for Hypertensive Diabetics), evaluating
the effects of MC-1 alone and in combination with an ACE Inhibitor
in control of blood pressure, metabolism and other endpoints in
diabetic patients with hypertension.
Medicure also has a medicinal chemistry based Drug Discovery program
focused on discovery and advancement of novel small molecule, anti-ischemics
and anti-thrombotics towards human clinical studies.
This news release
contains forward-looking statements that involve risks, which may
cause actual results to differ materially from the statements made,
and accordingly may be deemed to be forward-looking statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The forward-looking statements are
made as of the date hereof, and the Company disclaims any intention
and has no obligation or responsibility to update or revise any
forward-looking statements, whether as a result of new information,
future events, or otherwise.
For more information, please contact:
Derek Reimer
Chief Financial Officer
Don Bain
Director of Investor & Public Relations
Medicure Inc.
888-435-2220
204-488-9823 fax
info@medicure.com
Back to 2004 News Archives
